Medicure patent expiration

1. Aggrastat patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5733919 MEDICURE Compositions for inhibiting platelet aggregation
Oct, 2016

(7 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5733919 MEDICURE Compositions for inhibiting platelet aggregation
Oct, 2016

(7 years ago)

US5972967 MEDICURE Compositions for inhibiting platelet aggregation
Oct, 2016

(7 years ago)

US5965581 MEDICURE Compositions for inhibiting platelet aggregation
Oct, 2016

(7 years ago)

US5978698 MEDICURE Angioplasty procedure using nonionic contrast media
Oct, 2017

(6 years ago)

US6136794 MEDICURE Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
Jan, 2019

(5 years ago)

US6770660 MEDICURE Method for inhibiting platelet aggregation
May, 2023

(1 year, 4 months ago)




Drugs and Companies using TIROFIBAN HYDROCHLORIDE ingredient

Market Authorisation Date: 14 May, 1998

Treatment: A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in ...

Dosage: INJECTABLE; SOLUTION

How can I launch a generic of AGGRASTAT before it's drug patent expiration?
More Information on Dosage

AGGRASTAT family patents

Family Patents

2. Zypitamag patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8829186 MEDICURE Method for preparation of pitavastatin and pharmaceutical acceptable salts thereof
Jan, 2031

(6 years from now)




Drugs and Companies using PITAVASTATIN MAGNESIUM ingredient

Market Authorisation Date: 14 July, 2017

Treatment: NA

Dosage: TABLET

More Information on Dosage

ZYPITAMAG family patents

Family Patents